Moreover, given the role of NPC1L1 as the target of ezetimibe, exploring the use of ezetimibe as an adjuvant therapy in RCC could be one potential approach to inhibiting tumor progression and metastasis. The gene discussed is NPC1L1; the disease is neoplasm.